NDAORALCAPSULEPriority Review
Approved
Sep 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
NORPACE (disopyramide phosphate) by Pfizer is mechanisms of action disopyramide phosphate is a type 1 antiarrhythmic drug (i. Approved for documented ventricular arrhythmias, such, that and 1 more indications. First approved in 1977.
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORPACE (disopyramide phosphate) is a Type IA antiarrhythmic oral capsule approved in 1977 for treating documented ventricular arrhythmias. It decreases diastolic depolarization and increases action potential duration in cardiac cells, similar to procainamide and quinidine. The drug has no effect on adrenergic receptors but stabilizes cardiac electrical activity in patients with abnormal heart rhythms.
$0.032BPart D
LOE ApproachingDeclining
The product is approaching loss of exclusivity with minimal Part D activity (48 claims in 2023), indicating a mature, declining franchise with limited commercial expansion opportunity.
Mechanism of Action
Mechanisms of Action Disopyramide phosphate is a Type 1 antiarrhythmic drug (i.e., similar to procainamide and quinidine). In animal studies, disopyramide phosphate decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase…
Indications (4)
Worked on NORPACE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.